These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
244 related articles for article (PubMed ID: 12831788)
41. Idiosyncratic toxicity: the role of toxicophores and bioactivation. Williams DP; Park BK Drug Discov Today; 2003 Nov; 8(22):1044-50. PubMed ID: 14690635 [TBL] [Abstract][Full Text] [Related]
42. Program seeks to enlist physicians to flag questionable promotion of drugs. Mitka M JAMA; 2010 Jul; 304(1):28-9. PubMed ID: 20606140 [No Abstract] [Full Text] [Related]
43. Interpretation and considerations on the safety evaluation of human drug metabolites. Atrakchi AH Chem Res Toxicol; 2009 Jul; 22(7):1217-20. PubMed ID: 19563206 [TBL] [Abstract][Full Text] [Related]
44. Metabonomics techniques and applications to pharmaceutical research & development. Lindon JC; Holmes E; Nicholson JK Pharm Res; 2006 Jun; 23(6):1075-88. PubMed ID: 16715371 [TBL] [Abstract][Full Text] [Related]
46. A "White Knight" role for DMPK researchers in pharmaceutical discovery: maximization of biomarker and translational M&S activities. Teramura T Drug Metab Pharmacokinet; 2012; 27(4):365-7. PubMed ID: 23268314 [No Abstract] [Full Text] [Related]
48. The continuing search for proper perspective: whose reasonableness should be at issue in a prescription product design defect analysis? Cupp RL Spec Law Dig Health Care Law; 2000 Dec; (260):9-33. PubMed ID: 11149134 [No Abstract] [Full Text] [Related]
49. Pharmaceuticals in the environment. Sherer JT Am J Health Syst Pharm; 2006 Jan; 63(2):174-8. PubMed ID: 16390933 [No Abstract] [Full Text] [Related]
50. The HEALTH Act's FDA defense to punitive damages: a gift to drug makers or to the public? Levy E Fordham Law Rev; 2006 Mar; 74(4):2425-60. PubMed ID: 17115481 [No Abstract] [Full Text] [Related]
51. Drug discovery-background and foreground. Tishler M Clin Pharmacol Ther; 1973; 14(4):479-86. PubMed ID: 4723254 [No Abstract] [Full Text] [Related]
52. ICH discussion on pharmacokinetics and toxicokinetics and contributors. Ohno Y Drug Metab Pharmacokinet; 2013; 28(5):379-82. PubMed ID: 24162438 [No Abstract] [Full Text] [Related]
53. The current status of guidelines for clinical research from the viewpoint of the pharmaceutical industry. Dixon RB J Clin Pharmacol; 1977; 17(11-12):691-6. PubMed ID: 925189 [No Abstract] [Full Text] [Related]
54. When to conduct a renal impairment study during drug development: US Food and Drug Administration perspective. Huang SM; Temple R; Xiao S; Zhang L; Lesko LJ Clin Pharmacol Ther; 2009 Nov; 86(5):475-9. PubMed ID: 19844224 [TBL] [Abstract][Full Text] [Related]
56. The use of the dog in toxicity tests on pharmaceutical compounds. Parkinson C; Grasso P Hum Exp Toxicol; 1993 Mar; 12(2):99-109. PubMed ID: 8096722 [TBL] [Abstract][Full Text] [Related]
57. Editorial. Bioactivation of drugs: enzymes, reactive metabolites and adverse reactions. Orhan H Curr Med Chem; 2015; 22(4):406-7. PubMed ID: 25515506 [No Abstract] [Full Text] [Related]
58. Pharmacokinetic drug interaction studies must consider pharmacological heterogeneity, use of repeated dosing, and translation into a message understandable to practicing clinicians. de Leon J; Spina E; Diaz FJ J Clin Psychopharmacol; 2009 Jun; 29(3):201-5. PubMed ID: 19440070 [No Abstract] [Full Text] [Related]
59. Drug discovery. Kennedy D Science; 2004 Mar; 303(5665):1729. PubMed ID: 15031461 [No Abstract] [Full Text] [Related]
60. New DTCA Guidance--Enough to Empower Consumers? Robertson CT N Engl J Med; 2015 Sep; 373(12):1085-7. PubMed ID: 26287748 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]